COVID-19

In these exceptional circumstances,
what we do matters more than ever

Since the pandemic began, Grifols has made its expertise in plasma available to health authorities, governments, regulatory agencies and society in general. At Grifols, we believe this current and extraordinary situation requires healthcare companies like ours to strive further to serve patients and society.

For over a century Grifols has been a healthcare company at the vanguard of blood- and plasma-therapy development, with the aim of enhancing people's health and wellbeing.

At the forefront of clinical trials to create treatments, as well as screening tests, to mitigate the global COVID-19 pandemic

In Grifols we believe in the therapeutic potential of human plasma and its components. During this unprecedented health crisis, plasma from patients who have recovered from COVID-19, called convalescent plasma, has been identified as a therapeutic option that can potentially help combat the disease until a vaccine is available.

This plasma from recovered COVID-19 donors contains antibodies which are specific against SARS-CoV-2, the virus that causes COVID-19. These antibodies are proteins called immunoglobulins, which help the body fight the infectious disease.

Convalescent plasma can be used:

  • For direct transfusion.
  • To develop a medicine, a hyperimmune globulin.
COVID-19 CONVALESCENT PLASMA POTENTIAL THERAPIES COVID-19 CONVALESCENT PLASMA POTENTIAL THERAPIES

Anti-SARS-CoV-2 hyperimmune globulin

Grifols is applying its broad knowledge and deep expertise in producing immunoglobulines to manufacter a specific anti-SARS-CoV-2 hyperimmune globulin for COVID-19, whose safety and efficacy will be evaluated in upcoming clinical trials in the US and Europe.

Convalescent plasma for transfusion

In addition to the hyperimmune globulin, Grifols is also carrying out several clinical trials to evaluate the safety and efficacy of convalescent plasma for direct transfusion.

Helping our donors provide their valuable plasma

Grifols is collecting plasma from recovered COVID-19 patients through nearly 250 donor centers, the largest network in the U.S. Our experienced technicians across the country are specially trained and prepared to help our donors, whose generous and compassionate contributions enable us to develop potential treatments.

We're also proud to be part of a coalition of world-class medical and research institutions, blood centers, life science companies, philanthropic organizations and COVID-19 survivor groups that has come together to mobilize tens of thousands of people in the United States who have recovered from COVID-19 to donate their plasma. Visit TheFightIsInUs.org.

COVID-19 Diagnostic and Screening Tests

Enabling the detection of the novel coronavirus SARS-CoV-2 through diagnostic and screening tests.

 

Read more

Research

Supporting external research, such as Gigagen Inc.'s recombinant polyclonal antibodies therapy or that led by the IrsiCaixa, Barcelona Supercomputing Center (BSC) and Food and Agriculture Science and Technology Institute (IRTA-CReSA) consortium to discover vaccine prototypes and antibody therapeutics for SARS-CoV-2.

Community Support

Organizing  food drives to aid communities and providing donations of personal protection equipment to the areas most impacted by the pandemic. In addition, technical and logistical support to hospitals for the storage, preparation and dispensing of medicines as well as the refurbishment and expansion of facilities to treat patients with COVID-19.